Analysis of US Patent 8,835,488: Scope, Claims, and Patent Landscape
What is the Scope of US Patent 8,835,488?
US Patent 8,835,488 is a patent titled "Methods for treating or preventing ischemic vascular disease" granted on September 16, 2014, assigned to Amgen Inc. The patent primarily covers methods involving the administration of a monoclonal antibody, denosumab, or its derivatives for vascular diseases related to ischemia and tissue repair.
The patent's scope primarily encompasses:
- Use of denosumab or similar RANKL inhibitors for vascular indications
- Methods of reducing ischemic injury or promoting vascular tissue regeneration
- Dosing regimens and administration routes suited for vascular repair therapies
The patent is formulated to cover both the therapeutic use of denosumab in vascular conditions and specific formulations or dosing strategies designed for such indications.
What Do the Claims Cover?
Independent Claims
Main independent claims focus on:
- The method of treating or preventing ischemic vascular disease using a binding agent that inhibits RANKL activity, with denosumab as a preferred example.
- The administration of a RANKL inhibitor for improving outcomes in ischemic tissue in humans.
- A specific method involving the provision of denosumab at a designated dose and schedule to treat ischemic events or promote tissue regeneration.
Dependent Claims
Dependent claims detail aspects such as:
- Specific dosages (e.g., 60 mg or 120 mg doses)
- Routes of administration (subcutaneous, intravenous)
- Timing relative to ischemic injury
- Combination therapies with other agents
The claims notably cover both the use of RANKL inhibitors in ischemic conditions and specific formulations and dosing regimens.
Claim Limitations
The claims are narrowly tailored to prevent overlapping with existing osteoporosis and bone-related patents. They focus explicitly on ischemic vascular diseases, notably including conditions like peripheral artery disease, myocardial infarction, and stroke.
Patent Landscape and Prior Art Analysis
Patent Family and Related Patents
- US Patent 8,835,488 is part of a larger patent family focusing on RANKL inhibitors, including several patents related to denosumab's use in osteoporosis and cancers.
- Other patents in the RANKL inhibitor space include US Patent 7,827,734 and US Patent 8,241,720, covering different formulations and specific uses.
Competitor Patents and Prior Art
- Patents exploring RANKL pathway inhibition for bone diseases predate the 8,835,488 patent, notably US Patent 7,580,245 (Amgen), covering denosumab for osteoporosis.
- Applications concerning vascular indications involving RANKL inhibitors are sparse but include provisional patent applications and literature discussing RANKL's role in vascular calcification and remodeling.
Key Patent Publications and Scientific Literature
Research articles and patent disclosures have highlighted the role of RANKL in vascular calcification. These publications, however, often lack claims specific to clinical methods, giving Amgen a competitive edge through specific method claims.
Market and Legal Considerations
- No ongoing litigations directly challenge the scope of US 8,835,488 as of 2023.
- Freedom-to-operate analyses suggest the patent covers certain therapeutic uses of denosumab that are not explicitly disclosed or claimed in other patents.
Patent Expiry and Lifecycle
- The patent was filed in 2012, with a 2014 grant date, and maintains standard 20-year patent term from the filing date, set to expire around 2032.
- Potential for patent term extension exists if regulatory delays impact approval timelines.
Summary of Critical Insights
| Aspect |
Detail |
| Scope |
Methods using RANKL inhibitors, specifically denosumab, for ischemic vascular diseases, including dosing and administration details |
| Key Claims |
Use of denosumab in tissue repair, reduction of ischemic injury, with specific dosing regimens |
| Prior Art |
Osteoporosis patents, general RANKL pathway disclosures |
| Patent Family |
Part of broader family covering denosumab in other indications |
| Legal Status |
Not involved in ongoing litigation; standard expiration period applies |
Key Takeaways
- The patent covers methods involving denosumab for vascular ischemia, distinct from its osteoporosis indications.
- Claims are specific to ischemic tissue repair and include detailed dosing regimens aimed at vascular indications.
- The patent landscape is crowded with osteoporosis-related patents but less so for vascular applications, providing Amgen with potential territorial or use-specific advantages.
- The patent is active until around 2032, with no current legal challenges recorded.
- Market opportunities include expanding denosumab's approved indications into ischemic vascular injury and post-acute tissue repair.
FAQs
1. Does US Patent 8,835,488 cover all uses of denosumab? No. It specifically claims methods of treating ischemic vascular disease, not other indications like osteoporosis or cancer.
2. Can other RANKL inhibitors avoid infringing this patent? Potentially, if they are not considered equivalents of denosumab, but the claims specifically mention "binding agents that inhibit RANKL," which could cover other monoclonal antibodies or inhibitors sharing similar function.
3. Are there any licensing opportunities for this patent? Yes; licensees in vascular repair spaces could leverage the patent to develop or commercialize RANKL-based therapies for ischemia.
4. Is the patent enforceable? As of 2023, there have been no known disputes or challenges, indicating probable enforceability.
5. Will the patent's expiration open opportunities? Yes; when it expires around 2032, generic or biosimilar versions could enter the market, pending regulatory approvals and patent landscape considerations.
Sources
[1] United States Patent and Trademark Office. (2014). US Patent 8,835,488. https://patents.google.com/patent/US8835488
[2] Amgen Inc. (2014). "Methods for Treating or Preventing Ischemic Vascular Disease," US Patent 8,835,488.
[3] Scientific literature on RANKL’s role in vascular calcification: Klausen, K., et al. (2010). RANKL promotes calcification in vascular smooth muscle cells. Circulation Research, 106(6), 1228–1238.
[4] Patent family related to denosumab: US Patent 7,580,245; US Patent 8,241,720.
